GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $10.8 million for Q1 2023.

• In Q1 2023, Current Deferred Revenue rose 4.3% year-over-year to $10.8 million; the TTM figure through Mar 2023 stood at $10.8 million (up 4.3% YoY), while the FY2022 annual figure was $7.9 million, up 15.01% from the prior year.
• Current Deferred Revenue came in at $10.8 million for Q1 2023 at GoodRx Holdings, up from $7.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.5 million in Q2 2022 to a low of $3.5 million in Q4 2019.
• Average Current Deferred Revenue over 5 years is $8.5 million, with a median of $8.5 million recorded in 2021.
• Year-over-year, Current Deferred Revenue surged 98.44% in 2020 and gained 0.25% in 2021.
• Over 5 years, Current Deferred Revenue stood at $3.5 million in 2019, then surged by 98.44% to $6.9 million in 2020, then gained by 0.25% to $6.9 million in 2021, then grew by 15.01% to $7.9 million in 2022, then surged by 36.24% to $10.8 million in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $10.8 million in Q1 2023, $7.9 million in Q4 2022, and $11.0 million in Q3 2022.